文献速递脊柱关节炎

可行复合疾病活动度指标在银屑病关节炎患者日常临床实践中的结构效度与反应性

Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis.
PubMed 文献 · RMD Open · 2023-01-01

本研究在629例新诊断并接受常规治疗的银屑病关节炎患者中,检验3项视觉模拟量表(3VAS)和4项视觉模拟量表(4VAS)的结构效度与反应性。3VAS与4VAS的反应性与DAPSA、DAS28相似,与DAPSA、PASDAS、RAPID3呈强相关,且与PASDAS在12个月时对低疾病活动度分类的一致性最高。这是首个在早期银屑病关节炎观察队列中评估上述两工具性能的研究,4VAS可能因表面效度更佳而成为首选版本。

要点

  • 3VAS(ES=0.48,SRM 0.52)与4VAS(ES=0.48,SRM=0.50)的反应性与DAPSA、DAS28相似。
  • 3VAS与4VAS均与DAPSA(r=0.80-0.87)、PASDAS(r=0.89)、RAPID3(r=0.84-0.92)呈强相关。
  • 3VAS与4VAS在12个月时与PASDAS对低疾病活动度分类的一致性最高,4VAS可能因表面效度更佳而为首选版本。

核心结论

  • 这是首个在早期银屑病关节炎观察队列中评估3VAS与4VAS性能的研究,两者均显示出有前景的性能特征,与现有复合指标呈强相关且区分度良好。
  • 4VAS可能因表面效度更佳而成为首选版本。

研究设计与样本

  • 本研究为观察性队列研究,纳入629例新诊断并接受常规治疗的银屑病关节炎患者,评估3VAS与4VAS的结构效度与反应性。
  • 3VAS由医生总体、患者总体、患者皮肤三项组成,4VAS由医生总体、患者疼痛、患者关节、患者皮肤四项组成,各项均采用0-10分视觉模拟量表评分。
  • 采用维恩图检验3VAS/4VAS与其他复合指标对低疾病活动度状态的一致性,采用Spearman相关系数和标准化反应均值(SRM)及效应量(ES)评估结构效度与3个月间隔的反应性,并与多种患者报告结局指标进行比较。

主要发现

  • 3VAS的ES=0.48、SRM 0.52,4VAS的ES=0.48、SRM=0.50,两者反应性与DAPSA和DAS28相似。
  • 3VAS与4VAS均与DAPSA呈强相关(r=0.80-0.87),与PASDAS呈强相关(r=0.89),与RAPID3呈强相关(r=0.84-0.92)。
  • 3VAS与4VAS在12个月时对低疾病活动度分类与PASDAS的一致性最高。

临床怎么用

  • 作者认为4VAS可能因表面效度更佳而成为首选版本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a need for a widely accepted comprehensive disease activity measure for use in daily practice in patients with psoriatic arthritis (PsA). For this reason, the 3-item Visual Analogue Scale (3VAS) and 4-item Visual Analogue Scale (4VAS) were developed. This study aimed to test construct validity and responsiveness of the 3VAS and 4VAS in a population of patients with newly diagnosed PsA receiving usual care. METHODS: Components of the 3VAS (physician global, patient global, patient skin) and 4VAS (physician global, patient pain, patient joint, patient skin) were scored on 0-10 VAS scales. Agreement of low disease activity (LDA) state between 3VAS/4VAS and other composite measures was tested using Venn diagrams. Construct validity and responsiveness (3-month interval) were assessed using Spearman correlation coefficients and standardised response means (SRM) with effect sizes (ES), respectively, following hypothesis generation. Both 3VAS/4VAS were also compared with several patient-reported outcome measures. RESULTS: Data from 629 patients were used. Both 3VAS (ES=0.48, SRM 0.52) and 4VAS (ES=0.48, SRM=0.50) showed responsiveness similar to Disease Activity in PSoriatic Arthritis (DAPSA) and Disease Activity Score-28 (DAS28). Both measures had a strong correlation with DAPSA (r=0.80-0.87), Psoriatic Arthritis Disease Activity Score (PASDAS) (r=0.89) and Routine Assessment of Patient Index Data 3 (RAPID3) (r=0.84-0.92). 3VAS and 4VAS had the highest agreement with PASDAS in categorising patients to LDA at 12 months. CONCLUSION: This is the first study assessing the performance of the 3VAS and 4VAS in an observational cohort of patients with early PsA. Both measures have promising performance characteristics, showing strong correlations and good discrimination with existing composite measures. The 4VAS may be the preferred version with better face validity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kasiem FR, Kok MR, Luime JJ, et al. Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis. RMD Open. 2023. PMID: 37880177. doi:10.1136/rmdopen-2022-002972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。